Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul>
<li>TuHURA is a clinical-stage, oncology-focused biotechnology company ad-vancing innate immune agonists, checkpoint inhibitors &amp; antibody-drug conjugates (ADCs).</li>
<li>It offers the IFx platform technology featuring the IFx-2.0 tumoral injection delivery approach for Merkel cell carcinoma (MCC) &amp; the IFx-3.0 intravenous delivery approach for lymphoma.</li>
<li>IFx encodes a bacterial protein to be expressed in cancer cells, activating the innate immune system and subsequent cascade that may eliminate the tumor.</li>
</ul>


TuHURA is a clinical-stage, oncology-focused biotechnology company ad-vancing innate immune agonists, checkpoint inhibitors &amp; antibody-drug conjugates (ADCs).
It offers the IFx platform technology featuring the IFx-2.0 tumoral injection delivery approach for Merkel cell carcinoma (MCC) &amp; the IFx-3.0 intravenous delivery approach for lymphoma.
IFx encodes a bacterial protein to be expressed in cancer cells, activating the innate immune system and subsequent cascade that may eliminate the tumor.


TuHURA Biosciences, Inc. - Initiating an Immune Response